Report Overview

The global spinal cord stimulation market was valued at US$ 2.5 billion in 2021 and is expected to register a revenue CAGR of 7.9% during the forecast period.

Market Fundamentals

A spinal cord stimulation (SCS) is a pain relief procedure in which a modest electric current is used to inhibit nerve signals to the spine. An implantable neuromodulation device, commonly referred to as a "pain pacemaker," is used in this method to deliver electrical signals to spinal cord regions (dorsal columns). In cases of sciatica, cervical radiculopathy, failed back surgery syndrome (FBSS), reflex sympathetic dystrophy, and arachnoiditis, the device has a positive, symptomatic, and long-term outcome. SCS is recommended not to be used by those who have coagulation-related conditions or are on any anticoagulant medication.

[87343232]

Market Dynamic

The demand for spinal cord stimulators is rising because of the changing social behavior and an increasing number of injuries and traumas following spinal surgeries. The market revenue growth is also being driven by the increasing R&D activities to develop more sophisticated spinal cord stimulators. The major driver of the market revenue growth is the increasing number of patients suffering from failing back syndrome, chronic pain, and complex regional pain syndrome (CRPS). Additionally, the launch of new products and the rising number of patients suffering from chronic and neuropathic pain are propelling the revenue growth of the global spinal cord stimulator market.

However, the high cost of the device, side effects associated with the therapy, and the contraindication in patients undergoing anti-coagulant treatment, are likely to restrain the market revenue growth to some extent.

Market Ecosystem

The global spinal cord stimulation market has been analyzed from three perspectives: product, application, and region.

Spinal Cord Stimulation Market by Product

[12312312]

Based on the product, the global spinal cord stimulation is segmented into, rechargeable, and non-rechargeable devices. 

The rechargeable segment is expected to register the fastest revenue CAGR during the forecast period due to its affordability, adaptability, and ability to control pain through wireless remote procedures. 

The non-rechargeable segment is expected to register significant revenue growth during the forecast period, because of the rising R&D activities for improving the battery life of the devices and increased demand for treating failed back syndrome cases.

Spinal Cord Stimulation Market by Application

Based on application, the global spinal cord stimulation market is segmented into degenerative disc disease (DDD), complex regional pain syndrome (CRPS), arachnoiditis, failed back syndrome, and others. 

The CRPS segment dominates the global spinal cord stimulation market in terms of revenue share. The large revenue share of this segment can be attributed to the rising number of patients suffering from chronic pain. Furthermore, an increase in degenerative disc disease cases is expected to boost the segment revenue growth during the forecast period. 

Spinal Cord Stimulation Market by Region

Based on region, the global spinal cord stimulation market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

In terms of revenue share, the global spinal cord stimulation market is dominated by North America. The large revenue share of this region is attributed to the rise in CRPS, failing back syndrome, and chronic pain cases in this region. Additionally, the presence of well-established healthcare facilities, the availability of highly qualified doctors, the rising adoption of technologically advanced devices, and the increasing awareness of spinal cord stimulation therapy are expected to drive market revenue growth in this region. Furthermore, the rising reimbursement for device improvements such as wireless remote technology is favorably impacting the market expansion in the area.

Competitive Landscape

The prominent players  operating in the global spinal cord stimulation market are:

• Boston Scientific Corporation
• Medtronic plc
• Nevro Corp.
• Synapse Biomedical Inc.
• Neurosigma Inc.
• Nuvectra
• Stimwave LLC
• Abbott Laboratories

Strategic Developments

• In October 2022, FDA approved Nevro Corporation’s AI-powered spinal cord stimulator, equipped to treat non-surgical back pain cases. 
• In April 2022, Stimwave Technologies announced a partnership with Aspen Medical Products, to develop a wearable pain management accessory.

Frequently Asked Questions About This Report